Clinical Trials Browser

Phase 2/3 × osimertinib × Clear all

NCT07005102 2026-01-23

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Phase 2/3 Recruiting

Neoplasms

NCT05020769 2025-09-26

SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06908772 2025-04-03

Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

Phase 2/3 Not yet recruiting

Recurrence

NCT02959749 2018-02-14

Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer

Phase 2/3 Completed

Progression Free Survival